| 4.53 -0.13 (-2.79%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.78 |
1-year : | 7.77 |
| Resists | First : | 5.81 |
Second : | 6.65 |
| Pivot price | 4.73 |
|||
| Supports | First : | 4.44 |
Second : | 3.69 |
| MAs | MA(5) : | 4.73 |
MA(20) : | 4.85 |
| MA(100) : | 5.56 |
MA(250) : | 7.43 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4  |
| %K %D | K(14,3) : | 20.6 |
D(3) : | 24.7 |
| RSI | RSI(14): 31.7 |
|||
| 52-week | High : | 13.22 | Low : | 4.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RXST ] has closed below the lower bollinger band by 5.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 74.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.78 - 4.81 | 4.81 - 4.83 |
| Low: | 4.38 - 4.42 | 4.42 - 4.44 |
| Close: | 4.48 - 4.54 | 4.54 - 4.58 |
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Wed, 26 Aug 2026
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference - GlobeNewswire
Wed, 26 Aug 2026
RxSight management is scheduled to speak in Boston on Sept. 9 - Stock Titan
Thu, 13 Aug 2026
Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery? - Yahoo Finance
Wed, 05 Aug 2026
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Fri, 10 Jul 2026
RxSight: After Dropping To The Bottom, It's Time To Pick It Up (NASDAQ:RXST) - Seeking Alpha
Wed, 08 Jul 2026
RxSight: Alcon Deal Reshapes The Long-Term Growth Story (NASDAQ:RXST) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 42 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 104.3 (%) |
| Shares Short | 4,090 (K) |
| Shares Short P.Month | 3,880 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.32 |
| Profit Margin | -36.8 % |
| Operating Margin | -40.9 % |
| Return on Assets (ttm) | -10.5 % |
| Return on Equity (ttm) | -17.4 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 2.37 |
| Sales Per Share | 3.06 |
| EBITDA (p.s.) | -1.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -4.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.71 |
| Price to Sales | 1.47 |
| Price to Cash Flow | -8.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|